Login to Your Account



Serenex Raises $31M To Fund Mucositis And Hsp90 Programs

By Jim Shrine


Friday, June 29, 2007
Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription